Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5851-5860 Newer>

The Motley Fool August 27, 2009 Brian Orelli	The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list.
The Motley Fool August 27, 2009 Brian Orelli	Health-Care Reform: If You Can't Beat 'Em, Join 'Em? America could learn something from one country across the pond.
The Motley Fool August 26, 2009 Brian Orelli	Could Health-Care Reform Fix Your Sick Portfolio? For the health care sector there may be no greater unknown today than the final shape of health-care reform legislation.
The Motley Fool August 26, 2009 Brian Orelli	This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half.
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.
The Motley Fool August 26, 2009 Brian Orelli	Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia.
The Motley Fool August 25, 2009 Brian Orelli	Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again.
The Motley Fool August 25, 2009 Mike Pienciak	Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep?
The Motley Fool August 25, 2009 Brian Orelli	How to Keep From Losing Your Shirt More side effects for weight-loss drugs -- maybe.
The Motley Fool August 25, 2009 Brian Orelli	That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors.
<Older 5851-5860 Newer> Return to current articles.